Surveying Drug Pricing Reform: The Latest State Activity
By Deborah Gardner, Peter Holman Jr. and Dustin Schaefer (November 24, 2020, 4:48 PM EST) -- Drug pricing has come to the forefront of U.S. health policy, garnering attention from both major political parties and interest at both the federal and state level.
This is the second installment in a three-part article on drug pricing reform.
This article reviews the status of key state drug pricing reforms, where some of the more immediate impacts on drug pricing are occurring.
Specifically, we review four common state initiatives: pricing transparency; pharmacy benefit manager controls; drug importation; and value-based arrangements.
Our first article discussed drug pricing initiatives at the federal level. The third article will explore enforcement of federal pricing requirements....
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!